TK has officially completed the acquisition of an OTC (Over-the-Counter) manufacturing plant in California through its U.S. subsidiary, CTK USA Holdings. With this strategic move, CTK significantly strengthens its local manufacturing capabilities and expands its footprint in the North American OTC market.
The newly acquired facility is equipped to handle certified OTC product manufacturing and will be operated under the leadership of Chiho Choi, a seasoned beauty industry expert and former head of CTK’s cosmetics division. With his extensive experience in formulation R&D and global operations, CTK aims to provide high-quality, compliant, and market-ready solutions to global brands and partners.
CTK has invested approximately KRW 27.9 billion (~USD 20M) in this acquisition and is now positioned to offer full-service, U.S.-based OTC product development and manufacturing — from formulation to packaging — tailored for the evolving needs of beauty and personal care brands in North America.
As regulatory standards continue to evolve with the implementation of MoCRA (Modernization of Cosmetics Regulation Act), CTK has also established a cross-functional task force comprised of pharmacists, pharmaceutical compliance experts, and manufacturing specialists to stay ahead of U.S. compliance requirements.
In addition, CTK expects to create strong synergies with its global online B2B beauty platform, CTKCLIP, which now boasts over 40,000 brand users worldwide. The integration of an in-house OTC facility with digital sourcing and compliance tools enables CTK to offer next-level ODM and contract manufacturing services that meet the highest international standards.
This milestone marks CTK’s transition from a beauty innovation company to a full-spectrum global manufacturing partner.